US 12,268,724 B2
Methods and compositions for the prevention or treatment of Barth Syndrome
D. Travis Wilson, Needham, MA (US); and Mark Bamberger, Needham, MA (US)
Assigned to Stealth BioTherapeutics Inc., Needham, MA (US)
Filed by Stealth BioTherapeutics Inc., Needham, MA (US)
Filed on Aug. 23, 2023, as Appl. No. 18/454,319.
Application 18/454,319 is a continuation of application No. 17/371,475, filed on Jul. 9, 2021, granted, now 11,771,734.
Application 17/371,475 is a continuation of application No. 16/929,370, filed on Jul. 15, 2020, granted, now 11,083,772, issued on Aug. 10, 2021.
Application 16/929,370 is a continuation of application No. 15/626,255, filed on Jun. 19, 2017, granted, now 11,083,771, issued on Aug. 10, 2021.
Application 15/626,255 is a continuation of application No. 14/771,408, granted, now 9,687,519, issued on Jun. 27, 2017, previously published as PCT/US2014/019622, filed on Feb. 28, 2014.
Claims priority of provisional application 61/839,753, filed on Jun. 26, 2013.
Claims priority of provisional application 61/771,534, filed on Mar. 1, 2013.
Claims priority of provisional application 61/771,642, filed on Mar. 1, 2013.
Prior Publication US 2024/0156892 A1, May 16, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/00 (2006.01); A61K 38/06 (2006.01); A61K 38/07 (2006.01); A61K 45/06 (2006.01)
CPC A61K 38/06 (2013.01) [A61K 38/07 (2013.01); A61K 45/06 (2013.01)] 8 Claims
 
1. A method for reducing the number of mitochondria with abnormal mitochondrial ultrastructure, ameliorating abnormal mitochondrial ultrastructure, or maintaining mitochondrial organization in a subject having Barth Syndrome, comprising administering to the subject a therapeutically effective amount of the peptide D-Arg-2′6′-Dmt-Lys-Phe-NH2 or a pharmaceutically acceptable salt thereof.